Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

December 04, 2019

Alison J. Moskowitz, MD, discusses pivotal data for brentuximab vedotin in Hodgkin and T-Cell Lymphoma, as well as other ongoing developments in these paradigms.

December 03, 2019

Miguel-Angel Perales, MD, discusses the evolving role of CAR T-cell therapy in diffuse large B-cell lymphoma and follicular lymphoma.

December 03, 2019

Miguel-Angel Perales, MD, discusses the use of CAR T-cell therapy in diffuse large B-cell lymphoma and transformed follicular lymphoma.

December 03, 2019

Eytan M. Stein, MD, discusses the importance of measuring for measurable residual disease in acute myeloid leukemia.

November 27, 2019

Raajit K. Rampal, MD, PhD, discusses current available treatments for patients with polycythemia vera and myelofibrosis, as well as the unmet needs in this area of research.

November 27, 2019

Sergio A. Giralt, MD, discusses the current frontline standard of care for patients with multiple myeloma.

November 26, 2019

Sham Mailankody, MBBS, discusses ongoing research and recent advances in relapsed/refractory multiple myeloma.

November 26, 2019

Alexander Drilon, MD, discusses performing comprehensive sequencing in lung cancer.

November 25, 2019

Jamie E. Chaft, MD, explains how the PACIFIC trial has impacted the treatment of patients with stage III unresectable non–small cell lung cancer and the research being done to move immunotherapy into the neoadjuvant setting.

November 25, 2019

Sergio A. Giralt, MD, discusses the changing frontline treatment setting in multiple myeloma, how to determine transplant eligibility, and the utility of testing for minimal residual disease negativity.

November 23, 2019

Sham Mailankody, MBBS, discusses minimal residual disease negativity in multiple myeloma.

November 23, 2019

Anthony R. Mato, MD, MSCE, discusses differences between the use of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in chronic lymphocytic leukemia (CLL).

November 21, 2019

Anthony R. Mato, MD, MSCE, discusses ibrutinib-based combinations in chronic lymphocytic leukemia.

November 20, 2019

Mark E. Robson, MD, discusses the importance of educational efforts aimed at understanding the differences between biosimilars and biologics in oncology.

November 19, 2019

Azadeh Namakydoust, MD, discusses recent advancements in lung cancer and what the future holds.

November 18, 2019

Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses investigational neoadjuvant immunotherapy approaches in non–small cell lung cancer (NSCLC).

November 18, 2019

Azadeh Namakydoust, MD, FACP, thoracic oncologist, Memorial Sloan Kettering Cancer Center, discusses the use of next-generation sequencing (NGS) in lung cancer.

November 16, 2019

Miguel-Angel Perales, MD, discusses replacing autologous stem cell transplant with CAR T-cell therapy in diffuse large B-cell lymphoma.

November 15, 2019

Mark G. Kris, MD, discusses the impact of targeted therapy in patients with EGFR-mutant NSCLC and the encouraging activity that has been reported with checkpoint inhibitors in advanced squamous disease.

November 15, 2019

Sergio A. Giralt, MD, professor of medicine at Weill Cornell Medical College, and chief, Adult Bone Marrow Transplant Service, Melvin Berlin Family Chair in Multiple Myeloma, at Memorial Sloan Kettering Cancer Center, discusses methods of evaluating measurable residual disease (MRD) in multiple myeloma.